Pioneering preclinical work identified that pharmacological blockade of CSF1R using BLZ925 can promote the survival of animals with GBM [188], which can be used in combination with stereotactic radiotherapy for even more robust antitumor responses [189]. This evidence concerns the gene CSF1R and glioblastoma.